Comparison of Visual Prostate Symptom Score with the International Prostate Symptom Score and uroflowmetry parameters in assessing men with lower urinary tract symptoms in Dr. Cipto Mangunkusumo National General Hospital, Indonesia

Putra, Ida Bagus Oka Widya; Hamid, Agus Rizal Ardy Hariandy; Rasyid, Nur; Mochtar, Chaidir Arif; Umbas, Rainy

doi:10.1016/j.prnil.2018.09.001

Cited by 10 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Men with limited education can complete the VPSS faster and unassisted compared to the IPSS. The VPSS has seen increasing study in recent years, with good correlation to the IPSS demonstrated in countries including Thailand, 59 India, 60 Turkey, 61 Indonesia, 62 Uganda, 63 South Africa 64 and South Korea 65 …”

Section: Discussionmentioning

confidence: 99%

How international is the International Prostate Symptom Score? A literature review of validated translations of the IPSS, the most widely used self‐administered patient questionnaire for male lower urinary tract symptoms

Yao

Green

2021

LUTS

View full text Add to dashboard Cite

Objectives The International Prostate Symptom Score (IPSS) approaches its 30th anniversary. This ubiquitous clinical assessment tool is a standard in the assessment and research of lower urinary tract symptoms in men. The authors explore its history, development, and subsequent dissemination through validated translations across the world. An estimated global coverage is calculated and mapped according to language population. Methods Embase and Medline literature searches were performed, with further hand searches of grey literature and online resources. Twenty‐two abstracts and journal articles validating language translations of the IPSS were reviewed in full and tabulated. Language population data were gathered from an official database and mapped. Results The IPSS is available in 53 languages. Twenty‐seven languages have statistically or clinically validated translations for use in male patients. This corresponds to a conservative estimate of global population coverage of approximately 2.3 billion men, or 60% of the worldwide male population. Translation methodology involves forward and back translation. Statistical validation is performed with control patients. Cronbach's alpha is used for internal consistency, and Spearman's coefficient (p) or Pearson's coefficient (r) for test–retest reliability. Issues such as the emergence of altered versions deviating from original validated translations and translation difficulties due to cultural differences are observed. Further translational work is needed to validate versions of the IPSS in languages of the developing world. Conclusions The IPSS is the most prevalent patient‐administered questionnaire used in urology across the world. There is no other clinical tool seen to have similar coverage. This paper aims to provide a roadmap for future clinical tools to acquire a similar level of translation and dissemination.

show abstract

Section: Discussionmentioning

confidence: 99%

How international is the International Prostate Symptom Score? A literature review of validated translations of the IPSS, the most widely used self‐administered patient questionnaire for male lower urinary tract symptoms

Yao

Green

2021

LUTS

View full text Add to dashboard Cite

show abstract

“…15,16 Washino et al 17 found that the LH-RH agonist goserelin provided notable improvements by decreasing testosterone levels and reductions in prostate gland size. 17 The International Prostate Symptom Score (IPSS), a selfadministered questionnaire, 18 is a validated tool widely [19][20][21][22][23][24] Thus an IPSS score of 1-7 represents mild symptoms, 8-19 moderate symptoms, and 20-35 severe symptoms. 25 The IPSS includes an additional question that assesses the impact of urinary symptoms on the QoL of patients.…”

Section: Introductionmentioning

confidence: 99%

“…The International Prostate Symptom Score (IPSS), a self‐administered questionnaire, 18 is a validated tool widely 19 , 20 , 21 , 22 , 23 , 24 used in clinical practice and research to assess LUTS severity and its impact on QoL. It includes seven questions and was later modified with the addition of an eighth question on QoL.…”

Section: Introductionmentioning

confidence: 99%

Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta‐analysis

Barrett,

Birch

2023

BJUI Compass

View full text Add to dashboard Cite

ObjectiveThis systematic meta‐analysis aimed to assess the effectiveness of triptorelin therapy in reducing lower urinary tract symptoms (LUTS) in men with prostate cancer (PCa).MethodsThe Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines were followed. PubMed, Web of Science and EMBASE databases were searched for studies conducted between 2013 and 2023. Eligible studies included PCa patients undergoing androgen deprivation therapy (ADT) with triptorelin, with reported baseline and follow‐up International Prostate Symptom Scores (IPSS) and quality of life (QoL) data. The Newcastle–Ottawa Scale (NOS) was used to assess the risk of bias, and a random‐effects model was applied for the meta‐analysis.ResultsA total of 29 articles were identified, and three studies met the inclusion criteria. Triptorelin therapy showed a clinically significant reduction in IPSS over 48 weeks in PCa patients with moderate to severe LUTS. The meta‐analysis revealed a pooled effect size of 1.05 (95% CI: 0.65; 1.45), indicating a statistically significant improvement in LUTS. QoL also improved in patients receiving triptorelin therapy, although heterogeneity among the studies and a moderate to high risk of bias were noted.ConclusionTriptorelin therapy demonstrated a positive impact on LUTS in PCa patients. The meta‐analysis showed significant reductions in IPSS scores and improved QoL after 48 weeks of triptorelin treatment. However, the results should be interpreted cautiously due to study heterogeneity and potential biases. Further well‐designed studies are needed to confirm these findings and determine the optimal use of triptorelin for managing LUTS in men with PCa.Implications for PracticeTriptorelin therapy may offer an effective treatment option for men with PCa experiencing moderate to severe LUTS. Its positive impact on QoL can lead to improved patient well‐being and treatment adherence. Clinicians should consider triptorelin as a potential treatment choice, especially in patients who may be reluctant to undergo surgical interventions for their LUTS. However, careful patient selection and close monitoring are essential due to the observed study heterogeneity and risk of bias. Future research should focus on evaluating triptorelin's cost‐effectiveness and comparing its efficacy with other LH‐RH agonists in managing LUTS in PCa patients.Video Abstract: URL (Reviewers/Editors to select from) Link 1: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=071419c8-1ad5-4502-a222-b04300c2ca5eLink 2: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=b6305a8a-b977-4fcd-a69e-b04300bed728

show abstract

“…It is converted into a graph and doctor interprets its report. UFM gives interpretation of peak flow rate, average flow rate, time to peak flow, flow time, voiding time and voided volume is calculated as milliliters of urine passed per second 5 McConnell's practice guidelines have described that 125 to 150 ml minimum should be the voided volume to have accurate Uroflowmetry readings. Peak flow measurement (Qmax) of <10 ml/s is diagnosed as 'clinically obstructed Benign Prostatic Hyperplasia (BPH) patient 6 .…”

mentioning

confidence: 99%

Correlation of Uroflowmetry with Prostate Volume and International Prostatic Symptom Score (IPSS)

Raza¹,

Jamshed²,

Lakhani³

et al. 2022

J. Bahria Uni. Med. Dent. Coll.

View full text Add to dashboard Cite

Objective: To correlate Uroflowmetry with Prostate volume and International Prostatic Symptom Score in BPH patients and healthy adults in a subset of Karachi Population. Study Design and Setting: This is a crossectional study carried out at Ziauddin Hospital, Karachi over a period of 6 months. Methodology: In this study 100 Samples were taken through non probability convenience sampling. Inclusion criteria includes 40years and above. Sample initially was taken on the basis of International Prostatic Symptom Score i.e., less than 8 and greater than 8 score. Ultrasonography was performed. 65 Individuals with International Prostatic Symptom Score > 8 and Prostate volume <25 and individuals having symptom index < 8 and Prostate volume > 25ml went for Uroflowmetry. Mean and standard deviation was taken out for quantitative variables. Univariate analysis and Multiple Linear Regression applied to assess relationship between Uroflowmetry with Prostate volume and International Prostatic Symptom Score. Result: Mean age of patients was found to be 58±6 years. Mean International Prostatic Symptom Score was 11±4. Mean Prostate Volume was 28ml±5, mean Qmax was 14ml/s ±4. The correlation between Qmax and International Prostatic symptom score was found to be negative (-0.78) and statistically significant. No correlation was found between Prostate volume and Qmax. Conclusion: Qmax and International Prostatic Symptom Score are reliable tool for assessing Benign Prostatic Hyperplasia patients concluding that as Symptom Score increases Qmax decreases. Qmax showed no correlation with Prostate volume. Prostate volume assessed on Ultrasonography is not an authentic parameter for diagnosing BPH patients

show abstract

Comparison of Visual Prostate Symptom Score with the International Prostate Symptom Score and uroflowmetry parameters in assessing men with lower urinary tract symptoms in Dr. Cipto Mangunkusumo National General Hospital, Indonesia

Cited by 10 publications

References 18 publications

How international is the International Prostate Symptom Score? A literature review of validated translations of the IPSS, the most widely used self‐administered patient questionnaire for male lower urinary tract symptoms

How international is the International Prostate Symptom Score? A literature review of validated translations of the IPSS, the most widely used self‐administered patient questionnaire for male lower urinary tract symptoms

Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta‐analysis

Correlation of Uroflowmetry with Prostate Volume and International Prostatic Symptom Score (IPSS)

Contact Info

Product

Resources

About